[Anticancer effect of VP16-213 (etoposide) on three choriocarcinoma cell lines].
A new anticancer drug, VP16-213 was studied in vitro to determine its effect upon 3H-thymidine uptake and the survival rate of choriocarcinoma cells in comparison with the effect of MTX and Act-D. Three human choriocarcinoma cell lines, BeWo, HCCM-5 and SCH were used. The results were as follows; Serum VP16-213 levels were 10.3 +/- 1.19 micrograms/ml and 1.35 +/- 0.38 micrograms/ml at one hour and 12 hours after the administration of 100mg of VP16-213, respectively. In those three cell lines, VP16-213 suppressed cellular 3H-thymidine uptake by 70% as compared with the control. On the sixth day after exposure to VP16-213, the survival rate of choriocarcinoma cells was less than 10% in each of the three cell lines. One of the most prominent pharmacodynamic characteristics of VP16-213 was a rapid influx and efflux mechanism as seen in MTX. From the above, the anticancer effect of VP16-213 upon those three cell lines was supposed to be equal to or more than those of MTX and Act-D.
D002460:Cell Line; D002822:Choriocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004353:Drug Evaluation, Preclinical; D005047:Etoposide / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011247:Pregnancy; D013936:Thymidine / Q000378:metabolism; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D004273:DNA, Neoplasm; D005047:Etoposide; D013936:Thymidine